We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Sentinel Diagnostics

Sentinel Diagnostics develops and manufactures in-vitro diagnostic medical devices for routine analysis and specific ... read more Featured Products: More products

Download Mobile App





Sentinel Diagnostics Presents New Fully Automated Sample to Result System for Diagnosis of Viral Infections

By LabMedica International staff writers
Posted on 15 Nov 2022

Sentinel Diagnostics (Milano, Italy) is presenting its newly-launched SENTiNAT 200 fully automated sample to result system, and STAT-NAT SN200 Real-Time PCR assays for the quantitative detection of 10 viruses at MEDICA 2022. More...

The new SENTiNAT 200 and STAT-NAT SN200 kits represent the ideal solution for mid to large throughput laboratories engaged in the diagnosis of viral infections.

SENTiNAT 200 is a compact platform for DNA/RNA extraction, PCR set up and amplification that includes two integrated thermal cyclers and the FastFinder analysis software. The system combines throughput, automation and flexibility to better adapt to the various laboratory needs. It performs multi-parametric analysis of up to 15 viruses in the same run, processing from one up to 48 samples in four hours. The intuitive software that guides the operator through all the phases of the instrument set up, along with the barcode reader for samples and reagents help to reduce human error. The operator can access to the data available on the cloud anytime anywhere, to optimize reporting time while maintaining full control over the results.

SENTiNAT 200 is designed to work with STAT-NAT SN200 kits, based on the freeze-dried patented technology that allows long term stability at room temperature, making the assays more robust and simplifying reagent management in the laboratory. Also on display at the Sentinel booth at MEDICA 2022 is the recently launched SENTiFIT 800 high-throughput and fully automated solution for fecal immunochemical tests. SENTiFIT 800 represents the solution to help laboratories in the diagnosis of CRC as well as other digestive diseases.

“We developed the SENTiNAT 200 and STAT-NAT SN200 kits, all CE-marked, to offer a complete solution, that simplifies the routine activities of virology laboratories, including those dedicated to transplant patient,” said Marco Buonaguidi, Head of Sales and Marketing. “Today, we take a first step on a path that will see us committed to developing new parameters to satisfy the most challenging requests of our clients in molecular diagnostics.”

Related Links:
Sentinel Diagnostics 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.